Dongfu Pharmaceutical was established in May 2015 and is located in the National High-Tech Zone of Fuzhou City, Jiangxi Province. It is a new large-scale enterprise and a key tax-paying enterprise in the High-Tech Zone, covering an area of 62 mu (approximately 41,333 square meters). The company has a high-quality production environment and excellent equipment conditions, and has successively been awarded the titles of "Best Cleaner Production Enterprise" and "Municipal-Level Technological Innovation Center" by the Fuzhou Municipal Commission of Industry and Information Technology and the Fuzhou Municipal Bureau of Science and Technology. On February 28, 2016, the company obtained the national GMP (Good Manufacturing Practice) certification certificate. In 2017 and 2018, it was approved as a High-Tech Enterprise and a Technology-Based Small and Medium-Sized Enterprise respectively.

The company mainly focuses on the production of small-volume injections. It currently has two small-volume injection production lines: Line A (for glass ampoules) and Line B (for plastic ampoules). Its product range includes 5 varieties in 9 specifications, with Tropisetron Citrate Injection being an exclusive variety in China, along with other products such as Levocarnitine Injection, Lincomycin Hydrochloride Injection, Glucose Injection, and Sterile Water for Injection.

Among these products, the exclusive Tropisetron Citrate Injection obtained the "New Drug Certificate" issued by the National Medical Products Administration (formerly the State Food and Drug Administration) in 2010. Its core technology has obtained 5 national patents, and the company exclusively holds the independent intellectual property rights for the production of both the raw material and preparation of this variety in China. In addition, Levocarnitine Injection has won the "Jiangxi Provincial New Product Certificate" and the "Third Prize of Jiangxi Provincial Excellent New Product"; Lincomycin Hydrochloride Injection has also obtained the "Jiangxi Provincial New Product Certificate".

The company has an independent R&D team, with technical backbones accounting for 60% of its staff, and has a group of high-quality professional young and middle-aged talents. In the next 3-5 years, the company will continue to develop by integrating varieties within the group, changing external packaging materials, and selecting new varieties, aiming to capture a larger market share in this product segment.

Huiyinbi Group has always taken "Huiyinbi, Bi Huiyin" (meaning "Huiyinbi always delivers on its commitments") as its core culture, and adheres to the "rocket spirit" of being rapid, efficient and conducive to development, dedicated to producing high-quality and trustworthy medicines for the public. We will repay society with high-quality products and strive to gain a firm foothold in the domestic small-volume injection field.